Related Experiment Videos
Treating serum lipid abnormalities in high-priority patients
1Department of Medicine, University of Southern California School of Medicine, Los Angeles 90033.
Insights
Early normalization of serum lipid levels is crucial for patients with vascular disease. Lipid-lowering therapy can reduce mortality and improve atherosclerosis by targeting cholesterol and triglyceride levels.
Area of Science:
- Cardiology
- Vascular Medicine
- Pharmacology
Background:
- Patients with myocardial, cerebrovascular, or peripheral vascular disease require prompt normalization of serum lipid levels.
- Clinical trials demonstrate that lipid-lowering therapy can reduce coronary artery disease and overall mortality rates.
- This therapy has the potential to stabilize or reverse atherosclerosis progression.
Purpose of the Study:
- To outline the importance and methods of lipid level normalization in patients with vascular disease.
- To define target lipid levels for effective treatment.
- To identify therapeutic options for lipid-lowering therapy.
Main Methods:
- Initiating lipid normalization as soon as possible in affected patients.
- Implementing lipid-lowering therapy including dietary modification and pharmacologic agents.
- Managing nonlipid coronary risk factors concurrently.
Main Results:
- Lipid-lowering therapy effectively reduces coronary artery disease and overall mortality.
- Target low-density lipoprotein cholesterol levels: ≤130 mg/dL.
- Target triglyceride levels: ≤150 mg/dL; target high-density lipoprotein cholesterol: ≥52 mg/dL (men), ≥66 mg/dL (women).
Conclusions:
- Prompt initiation of lipid normalization is essential for patients with established vascular disease.
- Achieving specific lipid level targets can significantly improve cardiovascular outcomes.
- A combination of lifestyle changes and pharmacotherapy is recommended for comprehensive lipid management.
Abstract:
Normalization of serum lipid levels should be initiated as soon as possible in patients with myocardial, cerebrovascular, or peripheral vascular disease. Clinical trials indicate that coronary artery disease and overall mortality rates can be reduced and atherosclerosis stabilized or reversed by lipid-lowering therapy. Treatment should lower low-density lipoprotein cholesterol levels to 130 mg/dL or less and total triglyceride levels to 150 mg/dL or less and increase high-density lipoprotein cholesterol levels to at least 52 mg/dL in men and 66 mg/dL in women. Nonlipid coronary risk factors should be eliminated when possible. Lipid-lowering therapy may consist of dietary modification and drug treatment with colestipol hydrochloride (Colestid), cholestyramine (Cholybar, Questran), lovastatin (Mevacor), gemfibrozil (Lopid), and nicotinic acid (Nicolar).